Added to YB: 2025-11-12
Pitch date: 2025-11-06
NVO [neutral]
Novo Nordisk A/S
+6.61%
current return
Author Info
Fat Alpha Value Investing is a podcast that inveterviews top value investors who share their ideas. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 301.25
Price Target
332.00 (+3%)
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
value
Novo's problem isn't the drugs - Conservative FCF scenarios
NVO (overview): Stock dropped -4.5% on results. 2025 guidance: DKK 302-306B revenue (+4-5.5%), DKK 137B adj EBIT (44.6% margin vs 48.2% in 2024). High capex/intangibles spending pressures FCF to DKK 30-37B. Mgmt says nearing peak spend; normalized FCF could reach DKK 59-86B. DCF values stock DKK 332-381 vs current DKK 300.
Read full article (3 min)